Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

It is also FDA-authorised under an EUA as a third primary series dose in individuals 12 years old and above who have certain kinds of immunocompromises. The Pfizer/BioNTech bivalent COVID-19 ...

As the state faces a multimillion dollar measles outbreak in West Texas, the House Public Health Committee passes HB 1586 ...

After reviewing all clinical data for the medicine and consulting with regulators, Pfizer said it decided to halt research on it. The case occurred in a dose optimization trial, aimed at finding ...

Australian scientists have revealed why receiving a booster vaccine in the same arm as your first dose is more effective.

Pfizer said it halted development of danuglipron after discovering that a "participant in one of the dose-optimization studies experienced potential drug-induced liver injury." (REUTERS/Carlo ...

Pfizer’s dose-optimization studies of once-daily formulations of danuglipron (NCT06567327 and NCT06568731) met key pharmacokinetic objectives and confirmed a formulation and dose with the ...

Pfizer’s dose-optimization studies of once-daily formulations of danuglipron (PF-06882961) met key pharmacokinetic objectives. The study confirmed a formulation and dose that could deliver a ...

Pfizer (PFE) said Monday it will no longer develop its investigational pill for weight loss after detecting a "potential drug-induced liver injury" in a dose-optimization study participant.

Pfizer (NYSE:PFE) is overhauling its cardiometabolic ... was the right decision for the company after a patient in a dose-optimization study developed liver injury. He added that Pfizer would ...